Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 5;13:8165–8178. doi: 10.2147/IJN.S182998

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Niu et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

The effects of SVNs and SV on the ERK1/2 pathway.

Notes: SVNs and SV can increase the expression of p-ERK1/2 in the early stage of the experiment (A). On 1 day (B), 7 days (C), and 14 days (D), both SVNs and SV exhibited a significant, sustained inhibitory effect on the expression of the p-ERK1/2. In addition, the expression of p-ERK1/2 in each experimental group was inhibited significantly after the MG63 cells were pretreated with the ERK1/2 pathway inhibitor PD98059 (50 μM) prior to drug intervention (B–D). The results are the mean values of three independent measurements (±SD). ^*P<0.05 vs BCG; ^#P<0.05 SVNG vs SVG; ^▲P<0.05 drug vs drug + PD98059.

Abbreviations: BCG, blank control group; DFNG, drug-free nanomicelles group; p-ERK1/2, phosphorylated ERK1/2; SD, standard deviation; SV, simvastatin; SVG, simvastatin group; SVNs, simvastatin-loaded nanomicelles; SVNG, simvastatin-loaded nanomicelles group; t-ERK1/2, total ERK1/2.